NYSE:WAT - Waters Stock Price, Price Target & More

Waters trades on the New York Stock Exchange (NYSE) under the ticker symbol "WAT."

Waters announced that its Board of Directors has approved a share buyback plan on Tuesday, April 24th 2018, which allows the company to buyback $3,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 18.2% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's management believes its stock is undervalued.

Waters Co. (NYSE:WAT) posted its quarterly earnings results on Tuesday, April, 24th. The medical instruments supplier reported $1.59 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.55 by $0.04. The medical instruments supplier had revenue of $530.70 million for the quarter, compared to the consensus estimate of $534.17 million. Waters had a net margin of 1.14% and a return on equity of 25.80%. Waters's revenue was up 6.6% compared to the same quarter last year. During the same period last year, the business posted $1.46 EPS. View Waters' Earnings History.

Waters is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Waters.

Waters updated its FY18 earnings guidance on Tuesday, April, 24th. The company provided earnings per share (EPS) guidance of $8.10-8.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.19.

16 Wall Street analysts have issued twelve-month price targets for Waters' shares. Their predictions range from $180.00 to $230.00. On average, they anticipate Waters' share price to reach $204.7857 in the next year. This suggests a possible upside of 4.5% from the stock's current price. View Analyst Ratings for Waters.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Waters in the last year. There are currently 2 sell ratings, 10 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Waters include Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories, Inc. Class A Common Stock (BIO), Bio-Rad Laboratories, Inc. Class B (BIO.B), PerkinElmer (PKI), Integra Lifesciences (IART), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM) and Harvard Bioscience (HBIO).

Media stories about WAT stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Waters earned a media sentiment score of 0.17 on Accern's scale. They also gave press coverage about the medical instruments supplier an impact score of 47.56 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Waters' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (3.26%), Fenimore Asset Management Inc. (0.37%), Assenagon Asset Management S.A. (0.12%), Bank of Montreal Can (0.11%), Copper Rock Capital Partners LLC (0.08%) and Retirement Systems of Alabama (0.05%). Company insiders that own Waters stock include Arthur G Caputo, Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Ian King, Joann A Reed, Laurie H MD Glimcher, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Michael J Berendt, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Institutional Ownership Trends for Waters.

WAT stock was sold by a variety of institutional investors in the last quarter, including NN Investment Partners Holdings N.V., Baillie Gifford & Co., State of Alaska Department of Revenue, Fenimore Asset Management Inc., Retirement Systems of Alabama, Copper Rock Capital Partners LLC, Gateway Investment Advisers LLC and Raymond James Trust N.A.. Company insiders that have sold Waters company stock in the last year include Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Joann A Reed, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Insider Buying and Selling for Waters.

WAT stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Meag Munich Ergo Kapitalanlagegesellschaft MBH, DnB Asset Management AS, Bank of Montreal Can, Denali Advisors LLC, Fjarde AP Fonden Fourth Swedish National Pension Fund, IFM Investors Pty Ltd and Pennsylvania Trust Co. View Insider Buying and Selling for Waters.

Shares of WAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of WAT stock can currently be purchased for approximately $196.01.

Waters has a market capitalization of $15.52 billion and generates $2.31 billion in revenue each year. The medical instruments supplier earns $20.31 million in net income (profit) each year or $7.49 on an earnings per share basis. Waters employs 7,000 workers across the globe.

Waters' mailing address is 34 MAPLE STREET, MILFORD MA, 01757. The medical instruments supplier can be reached via phone at 508-478-2000 or via email at [email protected]